What it is: A small synthetic peptide derived from angiotensin research, studied for its proposed role in supporting synaptic connections and cognitive function through the HGF/Met pathway.
Research suggests: Preclinical studies showed cognitive improvements described as exceptionally potent in comparisons with BDNF; human data is essentially absent.
Best for: Cognitive enhancement researchers
Key thing to know: One of the most poorly studied compounds in this library for humans - meaningful evidence is preclinical only, and human safety data does not exist.
What is Dihexa?
Dihexa (also known as PNB-0408) is a small synthetic peptide from angiotensin IV research — specifically studies of the hepatocyte growth factor (HGF) signaling system and its receptor Met, which affect neuronal survival, synaptic plasticity, and cognition. It was developed at Washington State University and drew attention for its reported potency versus other cognitive-enhancement compounds in preclinical studies.
Researchers study Dihexa for cognitive enhancement, synaptogenesis (formation of new synaptic connections), neurogenesis, and reversal of cognitive deficits in preclinical studies of neurodegeneration. Its reputation in the nootropic research community is built primarily on preclinical data and claims of exceptional potency, claims that require careful evaluation given the complete absence of human clinical trial data.
How it works.
In research, the proposed mechanism has several parts.
HGF/Met pathway: Dihexa is proposed to positively modulate the HGF/Met signaling pathway, a system involved in neuronal growth, survival, and new synaptic connections. HGF/Met signaling promotes dendritic spine formation and synaptic plasticity — the structural changes underlying learning and memory. Research suggests Dihexa may potentiate this pathway, potentially supporting new synaptic connections in aging or cognitively compromised neural tissue.
In plain terms: Think of it as amplifying the brain's wiring and repair signaling, nudging neurons to form new connections rather than protect existing ones. Some research suggests Dihexa may be more potent than BDNF (brain-derived neurotrophic factor) in in vitro synaptogenesis assays. That claim draws interest and scrutiny, since cell-assay potency rarely predicts activity in living organisms.
A safety consideration: The HGF/Met pathway is also relevant to cancer biology, Met is a proto-oncogene and HGF/Met signaling is involved in cell proliferation and survival in multiple tissue types. This dual biology is an important consideration in the risk assessment for any HGF/Met modulating compound, including Dihexa.
What the research shows.
The research evidence breaks down as follows.
Preclinical only: Dihexa's evidence base is almost entirely preclinical. Rodent studies report significant improvements in spatial memory tasks (Morris water maze, radial arm maze), reversal of scopolamine-induced cognitive deficits, and improvement in aging-related cognitive decline models. The findings in preclinical studies have been consistent within the research group that developed the compound.
Potency claims: The potency claims — that Dihexa may be substantially more potent than BDNF in synaptogenesis assays — rest on in vitro cell culture data. Such in vitro comparisons are scientifically interesting but often fail to translate to in vivo potency, and even less reliably to human outcomes. No human clinical trials have been published as of 2025.
No human data: The complete absence of human data is the defining characteristic of Dihexa's evidence profile.
Biomarkers to review first.
These markers provide relevant baseline context for neurological health, stress response, and metabolic function before exploring Dihexa in a research context.
What it's commonly researched with.
In research contexts, Dihexa is most often discussed alongside other cognitive and neuroprotective compounds that target complementary neurological pathways. These combinations appear in community research discussions, not formal published combination trials.